

Table S1. *CYP2D6* genotype distribution in the study population of 997 Finnish patients undergoing day surgery

Predicted phenotype (%)	Activity score	Genotype (%)
PM (3.7%)	0	*3/*3 (0.1%), *3/*4 (0.4%), *3/*5 (0.1%), *4/*4 (2.1%), *4/*5 (0.7%), *4/*6 (0.3%)
IM (26.6%)	0.25	*4/*10 (0.3%), *5/*10 (0.1%), *6/*10 (0.1%)
	0.5	*3/*41 (0.2%), *3/*9 (0.1%), *4/*9 (0.5%), *4/*41 (0.9%), *5/*41 (0.3%), *10/*10 (0.1%)
	0.75	*9/*10 (0.1%), *10/*41 (0.1%)
	1	*1/*3 (3.3%), *1/*4 (8.4%), *1/*5 (1.6%), *1/*6 (0.8%), *2/*3 (1.0%), *2/*4 (4.2%), *2/*5 (0.9%), *2/*6 (0.8%), *3/*35 (0.6%), 4/*35 (1.7%), *41/*41 (0.1%), *5/*35 (0.1%), *6/*35 (0.1%), *9/*41 (0.1%)
NM (63.2%)	1.25	*1/*10 (1.2%), *2/*10 (1.0%), *10/*35 (0.1%)
	1.5	*1/*9 (1.5%), *1/*41 (2.8%), *1/*17 (0.1%), *2/*9 (0.4%), *2/*17 (0.1%), *2/*41 (1.1%), *35/*41 (0.4%), *9/*35 (0.3%)
	2	*1/*1 (15.7%), *1/*2 (21.9%), *1/*35 (3.5%), *1/*39 (0.1%), *1x2/*3 (0.1%), *1x2/*4 (0.5%), *1x2/*6 (0.1%), *2/*2 (7.8%), *2/*35 (2.4%), *2x2/*3 (0.1%), *2x2/*4 (0.6%), *35/*35 (0.9%)
	2.25	*1x2/*10 (0.1%), *2x2/*10 (0.1%)
UM (6.3%)	>2.25	*1x2/*1 (1.7%), *1x2/*2 (3.4%), *1x2/*2x2 (0.1%), *1x2/*35 (0.2%), *1x2/*35x2 (0.1%), *2x2/*2 (0.4%), *2x2/*35 (0.4%)
NA (0.2%)	NA	NA (0.2%)

IM, intermediate metabolizer; NA, undetermined; NM, normal metabolizer, PM, poor metabolizer; UM, ultrarapid metabolizer